RNA-Targeted Therapeutics Investment Synthesis

RNA-Targeted Therapeutics Investment Synthesis

Overview

RNA-targeted therapeutics represent one of the most rapidly advancing modality classes in neurodegenerative disease drug development. This synthesis provides an investment-focused analysis of this modality class, mapping antisense oligonucleotides (ASOs), RNA interference (RNAi) technologies, and RNA splicing modulators to disease indications, development stages, and funding landscapes.

This synthesis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Novel Therapeutic Modalities Synthesis](/mechanisms/novel-therapeutic-modalities-synthesis), and [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis) by providing modality-specific investment analysis.

RNA Therapeutic Modality Landscape

Modality Comparison Matrix

RNA-Targeted Therapeutics Investment Synthesis

Overview

RNA-targeted therapeutics represent one of the most rapidly advancing modality classes in neurodegenerative disease drug development. This synthesis provides an investment-focused analysis of this modality class, mapping antisense oligonucleotides (ASOs), RNA interference (RNAi) technologies, and RNA splicing modulators to disease indications, development stages, and funding landscapes.

This synthesis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Novel Therapeutic Modalities Synthesis](/mechanisms/novel-therapeutic-modalities-synthesis), and [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis) by providing modality-specific investment analysis.

RNA Therapeutic Modality Landscape

Modality Comparison Matrix

| Modality | Mechanism | Delivery Challenge | Duration | Development Stage | Cross-Disease Potential |
|----------|-----------|-------------------|----------|-------------------|------------------------|
| ASO (Antisense Oligonucleotides) | RNase H or splicing modulation | Moderate (LNA, 2'-MOE improvements) | 2-4 months | Phase 2-3 | High |
| siRNA | RNAi-mediated mRNA degradation | High (CNS penetration) | 3-6 months | Phase 1 | Moderate |
| miRNA Mimics/Antagomirs | miRNA regulation | High | Variable | Preclinical | Moderate |
| Splice-Modulating Small Molecules | Alternative splicing modulation | Low (CNS-penetrant) | Days | Phase 1-2 | High |
| mRNA Therapeutics | Protein replacement | High | Weeks | Preclinical | Moderate |
| saRNA | Gene activation | High | Weeks-Months | Preclinical | Low |

Investment Thesis

RNA therapeutics offer several compelling advantages for neurodegenerative diseases:

Therapeutic Target Rankings by Investment Signal

Tier 1: Highest Investment Priority (Score 9-10)

| Rank | Target | Modality | Disease | Evidence Score | Investment Score | Company/Program | Development Stage |
|------|--------|----------|---------|----------------|-----------------|-----------------|:-----------------:|
| 1 | SNCA | ASO | PD/DLB | 9.5 | 9.2 | Biogen (BIIB080), Ionis | Phase 1-2 |
| 2 | LRRK2 | ASO | PD | 9.0 | 8.8 | Ionis, Biogen | Phase 1 |
| 3 | MAPT (Tau) | ASO | AD/PSP | 9.2 | 8.7 | Ionis (ASO-mAPT), Biogen | Phase 1-2 |
| 4 | C9orf72 | ASO | ALS/FTD | 9.5 | 9.0 | Ionis, Biogen, Triplet | Phase 1-2 |
| 5 | SOD1 | ASO | ALS | 10.0 | 9.5 | Biogen/Ionis (Tofersen) | Approved/Phase 3 |

Tier 2: High Investment Priority (Score 7-8.9)

| Rank | Target | Modality | Disease | Evidence Score | Investment Score | Company/Program | Development Stage |
|------|--------|----------|---------|----------------|-----------------|-----------------|:-----------------:|
| 6 | GBA1 | ASO/siRNA | PD | 8.5 | 8.2 | Preclinical programs | Preclinical |
| 7 | HTT | ASO | HD | 9.0 | 8.5 | Roche/Tofersen | Phase 3 |
| 8 | GRN | ASO | FTD | 8.2 | 7.8 | Ionis | Phase 1 |
| 9 | ATXN2 | ASO | ALS | 7.8 | 7.5 | Neuase/Signature | Preclinical |
| 10 | FUS | ASO | ALS | 8.0 | 7.2 | Preclinical | Preclinical |

Tier 3: Emerging Investment (Score 5-7)

| Rank | Target | Modality | Disease | Evidence Score | Investment Score | Company/Program | Development Stage |
|------|--------|----------|---------|----------------|-----------------|-----------------|:-----------------:|
| 11 | TARDBP (TDP-43) | ASO | ALS/FTD | 7.0 | 6.5 | Preclinical | Preclinical |
| 12 | APP | ASO | AD | 6.5 | 6.2 | Preclinical | Preclinical |
| 13 | SNCA | siRNA | PD/DLB | 7.5 | 6.8 | Several programs | Preclinical |
| 14 | BIN1 | ASO | AD | 5.8 | 5.5 | Research stage | Preclinical |
| 15 | TMEM106B | ASO | FTD/ALS | 5.5 | 5.2 | Research stage | Preclinical |

Disease-Specific RNA Therapeutic Pipeline

Alzheimer's Disease

The AD RNA therapeutic pipeline focuses on amyloid-related targets and emerging genetic risk factors:

| Target | Modality | Company | Stage | Priority | Key Challenge |
|--------|----------|---------|-------|----------|----------------|
| SNCA | ASO | Biogen/Ionis | Phase 1 | High | Delivery to SNc |
| APP | ASO | Preclinical | Preclinical | Medium | Off-target effects |
| APOE4 | ASO | Various | Preclinical | Medium | Allele-specificity |
| TREM2 | miRNA | Research | Preclinical | Low | Mechanism complexity |

Investment Thesis for AD: ASO development for AD has been slower than PD/ALS due to less clear genetic causality. However, APOE4 and TREM2 represent promising genetic risk targets with strong human genetics support. The field awaits proof-of-concept from PD/ALS programs to derisk AD investments.

Parkinson's Disease

PD represents the most advanced RNA therapeutic pipeline for neurodegenerative diseases:

| Target | Modality | Company | Stage | Evidence | Investment |
|--------|----------|---------|-------|----------|------------|
| SNCA | ASO | Biogen | Phase 1-2 | High | Tier 1 |
| SNCA | siRNA | Various | Preclinical | Medium | Tier 3 |
| LRRK2 | ASO | Ionis/Biogen | Phase 1 | High | Tier 1 |
| GBA1 | ASO | Preclinical | Preclinical | Medium | Tier 2 |
| SNCA | miRNA | Research | Preclinical | Low | Tier 3 |

ALS/FTD Spectrum

The ALS/FTD pipeline is the most advanced for RNA therapeutics, with one approved therapy:

| Target | Modality | Company | Stage | Status | Investment |
|--------|----------|---------|-------|--------|------------|
| SOD1 | ASO | Biogen (Tofersen) | Approved | Landmark approval | Tier 1 |
| C9orf72 | ASO | Ionis/Biogen | Phase 1-2 | Leading pipeline | Tier 1 |
| ATXN2 | ASO | Signature/Nauase | Preclinical | Emerging | Tier 2 |
| FUS | ASO | Preclinical | Preclinical | Research | Tier 3 |
| TARDBP | ASO | Preclinical | Preclinical | Research | Tier 3 |

Investment Thesis for ALS: The Tofersen approval validates the ASO platform for ALS and creates a clear regulatory pathway. C9orf72 represents the largest genetically-defined patient population. The challenge is delivery to upper motor neurons and timing of intervention.

Splice-Modulating Small Molecules

Beyond oligonucleotide-based approaches, small molecules that modulate RNA splicing represent an emerging investment opportunity:

| Compound | Target | Mechanism | Disease | Stage | Company |
|----------|--------|-----------|---------|-------|---------|
| Risdiplam | SMN2 | Splicing activation | SMA | Approved | Roche |
| Branaplam | SMN2 | Splicing activation | Preclinical-AD | Phase 1 | Novartis |
| Pyridone 6 | LRRK2 | Splicing modulation | PD | Preclinical | Academic |
| Compound 1 | MAPT | Exon skipping | AD/PSP | Preclinical | Various |

Investment Thesis: Small molecule splicing modulators offer advantages of CNS penetration and oral bioavailability. However, achieving specificity for disease-relevant splicing events remains challenging. The success of risdiplam in SMA provides proof-of-concept, but extension to neurodegenerative diseases requires target validation.

Delivery Technology Investment Analysis

Current Delivery Challenges

| Challenge | Impact | Solution Approaches | Investment Priority |
|-----------|--------|---------------------|---------------------|
| CNS Penetration | Critical | LNA modifications, conjugates, intrathecal | High |
| Neuronal Uptake | High | AAV, exosomes, peptides | High |
| Duration of Effect | Medium | GalNAc, sustained release | Medium |
| Off-Target Effects | High | Chemical modifications, SELEX | High |

Technology Platform Rankings

| Platform | Advantages | Limitations | Companies | Investment Score |
|----------|-----------|-------------|-----------|-----------------|
| 2'-MOE ASO | Well-validated, moderate delivery | Requires intrathecal | Ionis, Biogen | 9.0 |
| LNA ASO | Higher potency, CNS penetration | Toxicity concerns | Ionis | 8.5 |
| GalNAc Conjugates | Liver targeting, subcutaneous | Limited CNS utility | Several | 7.0 |
| AAV-siRNA | Long-duration, neuronal tropism | Immunogenicity, manufacturing | Various | 7.5 |
| Exosome-siRNA | CNS penetration potential | Manufacturing, standardization | Emerging | 6.0 |

Investment Priority Matrix

Execute (High Conviction)

| Target | Disease | Modality | Rationale |
|--------|---------|----------|-----------|
| C9orf72 | ALS/FTD | ASO | Largest genetic population, strong genetics, proof-of-concept from SOD1 |
| SNCA | PD/DLB | ASO | Direct disease mechanism, high unmet need, Biogen commitment |
| LRRK2 | PD | ASO | High genetic validity, kinase inhibitor learnings transfer |

Monitor (Track Closely)

| Target | Disease | Modality | Rationale |
|--------|---------|----------|-----------|
| MAPT | AD/PSP | ASO | Tau is validated, ASO platform proven, but competition from immunotherapy |
| GRN | FTD | ASO | Strong genetics, but small patient population |
| HTT | HD | ASO | Roche commitment, but late-stage development |

Explore (High Upside)

| Target | Disease | Modality | Rationale |
|--------|---------|----------|-----------|
| APOE4 | AD | ASO/miRNA | Large population, genetic certainty |
| TREM2 | AD | miRNA | Genetic risk, microglial mechanism |
| Multiple targets | AD | Platform approach | Diversified risk |

Company Pipeline Analysis

Major Player Programs

| Company | Pipeline Focus | Stage | Key Assets | Investment |
|---------|---------------|-------|------------|------------|
| Biogen/Ionis | ASO leader | Multiple | Tofersen, BIIB080, BIIB105 | Tier 1 |
| Roche | HTT, splicing | Phase 3 | Tominersen (withdrawn), Risdiplam learnings | Tier 1 |
| Triplet Therapeutics | C9orf72 | Phase 1 | C9orf72 ASO | Tier 2 |
| Neuase Therapeutics | ATXN2 | Preclinical | ATXN2 ASO | Tier 2 |
| Wave Life Sciences | ASO platform | Multiple | PRIC, stereopure ASOs | Tier 2 |

Emerging Biotech Opportunities

| Company | Focus | Differentiation | Risk Level |
|---------|-------|----------------|------------|
| Cerevel | LRRK2 small molecule | Oral delivery | Medium |
| AriBio | Multiple targets | ASO platform | High |
| Prilenia | HTT | Alternative approach | Medium |

Cross-Disease Investment Analysis

Disease Prioritization by Investment Attractiveness

| Disease | Genetic Target Count | Clinical Stage Assets | Investment Climate | Overall Score |
|---------|---------------------|----------------------|-------------------|---------------|
| ALS | 5+ (C9orf72, SOD1, FUS, TARDBP, ATXN2) | 1 approved, 2+ Phase 1-2 | High | 9.2 |
| PD | 4+ (SNCA, LRRK2, GBA, SNCA duplication) | 1 Phase 1-2 | Very High | 8.8 |
| FTD | 3 (C9orf72, GRN, MAPT) | 1 Phase 1 | High | 7.5 |
| HD | 1 (HTT) | 1 Phase 3 (withdrawn) | Medium | 6.5 |
| AD | 3+ (APP, APOE4, TREM2) | Preclinical only | Medium-High | 6.0 |

Cross-Disease Opportunities

| Target | Diseases | Platform Synergy | Investment Priority |
|--------|----------|-----------------|---------------------|
| C9orf72 | ALS, FTD | Same ASO, different doses | High |
| MAPT | AD, PSP, CBD | Same mechanism | High |
| TDP-43 | ALS, FTD | Same proteinopathy | Medium |
| Neuroinflammation targets | AD, PD, ALS | Shared pathways | Emerging |

Knowledge Gaps and Research Priorities

Critical Gaps

Research Priorities

Investment Implications

The RNA therapeutic modality for neurodegenerative diseases represents a high-risk, high-reward investment category:

• Derisked elements: Platform technology (Ionis), regulatory pathway (Tofersen), manufacturing
• Key risks: CNS delivery, patient selection, competition from other modalities
• Recommended strategy: Diversified portfolio across targets and companies, with focus on ALS/PD where genetic causality is strongest

References

Cross-Links

• [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings)
• [Novel Therapeutic Modalities Synthesis](/mechanisms/novel-therapeutic-modalities-synthesis)
• [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis)
• [Investment-Evidence Convergence Analysis](/mechanisms/investment-evidence-convergence-analysis)
• [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains)
• [RNA-Targeted Therapies for Neurodegeneration](/mechanisms/rna-targeted-therapies-neurodegeneration)
• [C9orf72 ALS FTD Causal Chain](/mechanisms/c9orf72-rna-foci-dipeptide-repeats-als-ftd-causal-chain)
• [SOD1 ALS Causal Chain](/mechanisms/sod1-superoxide-dismutase-als-causal-chain)
• [Alpha-Synuclein Pathway](/mechanisms/synuclein-pathway-parkinsons)
• [LRRK2 Kinase and Autophagy Pathway](/mechanisms/lrrk2-kinase-autophagy-pathway)